We are thrilled to announce that Dr. Nir Shoham-Hazon, MD, the Co-Founder, CEO, and Scientific Director of Hexiris, has been honored with the prestigious 2024 ASCRS Educator Award. This recognition stands as a testament to Dr. Shoham-Hazon’s dedication, expertise, and outstanding contributions to the field of ophthalmology. The American Society of Cataract and Refractive Surgery…
DIEPPE, New Brunswick, April 02, – Hexiris Inc. (“Hexiris” or the “Company”), a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques, has joined Hexiris’s Scientific Committee. “We are proud that Dr. Harasymowycz has agreed…
DIEPPE, New Brunswick, Oct. 30, 2023 – Hexiris Inc. (“Hexiris” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris’s Scientific Committee. Dr. Ahmed is globally renowned for his skills and groundbreaking work in the diagnosis…
Glaucoma is the third leading cause of blindness and a leading cause of irreversible blindness worldwide. The global rate of glaucoma is expected to increase 39% to over 111 million by 2040. Glaucoma is rarely symptomatic until advanced irreversible optic nerve damage has already occurred. The main recognized, and the only modifiable, risk factor for…
Glaucoma can be treated with medications, laser or surgery. The first line of treatment consists of either IOP-lowering drop medications or laser. However, many patients suffer from refractory high IOP or glaucoma progression despite maximum tolerated medical treatment. In these cases, surgery is the only option left to achieve satisfactory IOP control. Traditionally, filtration surgery…
MIGS procedures use microscopic-sized equipment and tiny incisions. While they reduce the incidence of complications, some degree of effectiveness is also traded for increased safety. Nevertheless, current MIGS devices serve an unfilled niche given the alternative traditional treatments: Eye drops have shown poor patient compliance and have side effects. Laser therapy has a high failure…
